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Justice and Research on Controlled Substances with HIVC Persons
Leslie Francis and John Francis, University of Utah
Andreae and colleagues (2016) argue in defense of research involving the use of
controlled substances for pain and other symptom control in HIVC patients
by raising and defusing selected ethical and legal concerns about this research.
While we do not dispute the importance of the research, we are concerned that
their discussion construes the research and concomitant issues it raises too
narrowly, particularly with respect to data use and confidentiality. In this brief
comment, we note and briefly explore five additional issues about data collection
and use with HIVC populations that, we believe, are critical to building a case
for research with HIVC patients: data availability, data protection, risks of
stigmatizing inferences about individuals, potential mismatches between
research participants and research beneficiaries, and standards for
interventional versus non-interventional research. We begin with two
background observations, about the HIVC population and the nature of the
research examined by Andreae and colleagues.
The demographics of the HIVC population pose issues of justice. It is well
known in the United States that African-Americans are the racial group most
affected by HIV. According to recent Centers for Disease Control and
Prevention (CDC) statistics
(http://www.cdc.gov/hiv/group/racialethnic/africanamericans), AfricanAmericans account for an estimated 44% of new HIV infections although they
are only 12% of the population; the rate of new infections among African
American males in 2010 was 7 times that of white males and twice that of
Latino males. For African-American women, rates of new infections are 20
times that of whites and 5 times those of Latinos. Estimates are that one in
16 African-American men and 1 in 32 African-American women will be
diagnosed with HIV at some point during their lives. Lower percentages of
African Americans are linked to care, remain in care, receive appropriate
prescriptions of antiretroviral therapy, and achieve viral suppression. These
factors, together with the increased prevalence of other sexually transmitted
diseases (STDs), unawareness of HIV status, and missed opportunities for
treatment as prevention, contribute to increased burdens of disease in this
population. Perhaps less well known in the United States are European data
that HIV disproportionately affects migrants; in many West European
countries more than half of new HIV diagnoses were in this population
(European Centre for Disease Prevention and Control 2013).
Second, the research model that Andreae and colleagues discuss is
primarily interventional, most likely randomized controlled trials evaluating
the safety and efficacy of controlled substances in selected patient

populations. While such trials have been considered the gold standard, their
prominence has recently been questioned. Issues include enrollment barriers,
bias in study design or analysis, unwillingness to be randomized and other
ethical or practical questions about randomization, whether study
populations and conditions mirror real-world conditions such as adherence,
endpoint selection, and inability to detect low-frequency events. All of these
issues are likely to be present in research with HIVC populations, given the
demographics just presented (West et al. 2008). Donnell and colleagues
(2013), for example, recommend considering adherence in designing studies
of pre-exposure prophylaxis for HIV.
It may therefore be important to consider possibilities for types of research
other than clinical trials of prohibited drugs or drugs of uncertain legal
status. New statistical techniques of data analysis are enabling research using
existing patient records that controls more effectively for selection bias
(West et al. 2008). Data analyses in the 24 U.S. jurisdictions now allowing
medical cannabis might provide evidence of safety and efficacy of cannabis
use in HIV patients, to take one example. There are also possibilities of
building on the extensive efforts to study methods for increasing willingness
to be tested for HIV or to stay in HIV treatment. Results from such research
might help build the case for federal support of the drug trials considered by
Andreae and colleagues. Our suggestion here is that researchers should
consider creative methods to avoid the more direct legal challenges of
concern to Andreae and colleagues. The goal is to devise strategies that are
within the legally available world to build the case for testing proscribed
drugs for treating serious pain. But there are barriers and ethical concerns
here as well, to which we now turn.
1.

2.

Data availability. In addition to the HIV population demographics that
suggest that many are unaware of their status or not in care—so data
may simply not be available—there may be special legal constraints on
data involving treatment of patients using a controlled substance. The
Substance Abuse and Mental Health Services Act (SAMHSA) part 2
regulation imposes stringent consent requirements on disclosure of
information about patients treated in substance abuse facilities
receiving federal funds; it also imposes special requirements on
research use of this data. These restrictions may make it more difficult
to conduct research on HIV patients treated for substance abuse in
these facilities.
Data protection. As Andreae and colleagues indicate, the level of legal
protection afforded by certificates of confidentiality is uncertain
(Check et al. 2014). Deaths from abuse of opioids—both legal and
illegal—are recognized as an important public health problem in the
United States today (National Institute on Drug Abuse [NIDA] 2014)

3.

4.

5.

Drug use, drug diversion, and drug sales are an area of particular
interest to police and prosecutors. Despite emphasis on the importance
of education and public health efforts (NIDA 2014), efforts at
investigation, mandated treatment, and even prosecution may be
expected to intensify as well (Levulis 2015). Wolf et al. (2015) document
the importance of clarifying confidentiality protection; enhanced
protections are especially critical for doubly sensitive data such as
information about patients who both are HIV positive and use controlled
substances.
Risks of stigmatizing inferences. Particularly when data sets are
combined, novel and unanticipated inferences may appear. These
inferences appear from a constellation of factors: that if a person has
characteristics a-1 to a-n, the person also has characteristic a-nC1. To
be sure, these inferences are likely to be probabilistic and with different
levels of confidence. Nonetheless, if the inferred characteristic is
troublesome, it may be stigmatizing. Importantly, these risks of stigma
for individuals may arise even from research with de-identified data,
without efforts to re-identify individuals in the data, and regardless of
whether the individual about whom the inference was drawn was in the
original data set. A poignant example from the history of HIV is
inferences that were drawn about Haitians from data about original
disease incidence (Capo' 2013). Researchers should recognize the
possibility of these risks of stigma, the possibility that they might
reduce willingness to participate, and take steps to communicate
research in ways that mitigate these risks.
Mismatches between participants and beneficiaries of research. When
people permit data to be used in research, or when data about them are
used without consent, they contribute to an overall public good. As a
matter of minimal fairness it is reasonable to think that they should not
be shut out from receiving the benefits of the good to which they
contribute (Francis and Francis 2014). Given the demographic
characteristics of the population with HIV—including the
demographics of those who remain unaware of their status or who are
not consistently in care—along with other data about racial and ethnic
disparities in access to care more generally, such unfair mismatches are
a genuine possibility with any HIV research. Where the research
involves additional risks, such as research with HIV-positive people
who also use controlled substances, attention to these fairness concerns
is imperative.
Interventional versus non-interventional research standards. Debates
about whether the standards for protecting individuals in interventional
research should differ from those appropriate to protecting individuals
in non-interventional research are ongoing. The recent Common Rule
NPRM, 80 Fed. Reg. 53933 (Sept. 8, 2015), proposes adding as a new

category of exempt research secondary research use of identifiable
private information originally collected as part of a non-research
activity, where notice of such possible use was given and applicable
privacy protections are in place including heightened protections for
sensitive information. The uncertainty surrounding certificates of
confidentiality suggests that risks may be attendant on this strategy,
however.
Building the case for research improving pain management in HIV patients is an urgent
matter. Interventional research with controlled substances may need to be
complemented with other research strategies, given existing legal risks and barriers.
These complementary strategies— along with the research discussed by Andreae and
col- leagues—require attention to the additional barriers we have explored in this
comment. Ethical questions about this research must not be framed primarily as a binary
choice between liberty and the need to solve a critical social problem. Considerations of
justice must be at the fore, most notably risks to participants such as individuals newly
infected with HIV who are among the most vulnerable of populations in the United
States, in Europe, and else- where. Addressing these considerations of justice requires
longer term strategies such a research on pain control in less vulnerable populations,
non-interventional research, or other research methodologies that although not gold
standard may still produce findings of value. Even partial or imperfect results may help
build the case for reforming public policies that govern experimentation with controlled substances. There is value in the adoption of a risk- averse approach to research
on controlled substances with HIV-infected patients so that these doubly vulnerable
patients are not placed in legal harm’s way.
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